Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 6.5% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price was up 6.5% during mid-day trading on Thursday . The company traded as high as $19.13 and last traded at $19.46. Approximately 16,710 shares changed hands during trading, a decline of 93% from the average daily volume of 237,331 shares. The stock had previously closed at $18.27.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating for the company. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reaffirmed a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $54.33.

Dianthus Therapeutics Price Performance

The business has a 50-day moving average of $21.91 and a 200 day moving average of $24.29. The company has a market cap of $642.18 million, a PE ratio of -8.00 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $556,000. Barclays PLC increased its position in Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after acquiring an additional 33,185 shares during the last quarter. HighVista Strategies LLC purchased a new stake in shares of Dianthus Therapeutics in the third quarter valued at $542,000. State Street Corp lifted its holdings in shares of Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after acquiring an additional 413,425 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after purchasing an additional 97,362 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.